Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells
Sandra Handgraaf, … , Jacques Philippe, Yvan Gosmain
Sandra Handgraaf, … , Jacques Philippe, Yvan Gosmain
Published April 5, 2018
Citation Information: JCI Insight. 2018;3(7):e98569. https://doi.org/10.1172/jci.insight.98569.
View: Text | PDF
Research Article Endocrinology Metabolism

17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells

  • Text
  • PDF
Abstract

Clinical and experimental data indicate a beneficial effect of estrogens on energy and glucose homeostasis associated with improved insulin sensitivity and positive effects on insulin secretion. The aim of the study was to investigate the impact of estrogens on proglucagon-producing cells, pancreatic α cells, and enteroendocrine L cells. The consequences of sexual hormone deprivation were evaluated in ovariectomized mice (ovx). Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E2) treatment. Indeed, E2 increased oral glucose–induced GLP-1 secretion in vivo and GLP-1 secretion from primary culture of mouse and human α cells through the activation of all 3 estrogen receptors (ERs), whereas E2-induced GLP-1 secretion from mouse and human intestinal explants occurred only by ERβ activation. Underlying the implication of ERβ, its selective agonist WAY20070 was able to restore glucose tolerance in ovx mice at least partly through plasma GLP-1 increase. We conclude that E2 directly controls both α- and L cells to increase GLP-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of ERβ agonists to prevent type 2 diabetes.

Authors

Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain

×

Figure 5

Effects of estradiol on intestinal L cells of ovx mice in vivo and in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Effects of estradiol on intestinal L cells of ovx mice in vivo and in vi...
Relative Gcg and Pcsk1/3 mRNA levels (n = 6 animals in each group) (A) and GLP-1 cellular contents were measured from sorted intestinal L cells of ovx+vehicle (white bars, n = 5) and ovx+E2 (red bars, n = 5) mice (B). L cell numbers (Venus+ cells) from the small intestine were also evaluated by FACS (n = 7 animals in each group) (C). GLP-1 levels were quantified in supernatants and contents from primary cultures of mixed intestinal cells (D) of ovx mice, cultured for 48 hours with vehicle DMSO (white bars, n = 11) or with 17β-estradiol (E2, 1 × 10–8 mol/l, red bars, n = 10) after 2 hours of continuous release in complete fresh medium. Two-tailed Student’s t test statistical analyses. *P ≤ 0.05 for ovx+vehicle vs. ovx+E2 mice, and for DMSO- vs. E2-treated mixed cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts